Response to: Comment on “48-Week Outcome after Cessation of Nucleos(t)‎ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse”

Abstract EN

We appreciate the interest of Yafei Guo and colleagues [1] in our publication [2].

We agree with Guo et al.

that nucleos(t)ide analogues (NAs) cessation can be recommended in chronic hepatitis B (CHB) patients who are relatively younger and have relatively low serum hepatitis B surface antigen (HBsAg) levels and that it may be more effective to add on interferon treatment as an immune modulation rather than NAs cessation for CHB patients with low-level HBsAg.